The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Triggering global regulatory submissions this year for the treatment of obesity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Phase 1 dosing is expected to finish by the end of 2025
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Subscribe To Our Newsletter & Stay Updated
